Biocross is a biotechnology research company dedicated to the development of new biomarkers for the diagnosis of neurodegenerative diseases.

Our goal is to generate shareholder value by developing new tools that meet currently unmet needs in the diagnosis of dementia, reaching patients and physicians around the world, and providing benefits for the company, the scientific community, and patients.

This document outlines the reasons why Biocross is a leading company in Alzheimer’s disease diagnostics and is considered a first choice for investors in biotechnology.